Added to YB: 2026-08-07
Pitch date: 2026-08-05
STVN [neutral]
Stevanato Group S.p.A.
+1.5%
current return
Author Info
Care & Capital is a 23 year old value investor and Healthcare Equity Analyst in training. Sign up for the newsletter.
Company Info
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Market Cap
$4.8B
Pitch Price
$19.99
Price Target
N/A
Dividend
0.31%
EV/EBITDA
16.50
P/E
35.53
EV/Sales
4.18
Sector
Life Sciences Tools and Services
Category
growth
Stevanato Group ($STVN) – Reports Q2 2026 earnings
STVN (earnings): Q2'26 rev +8% to €302M (+10% cc); HVS +16% to €135.9M (45% of total, 51% of BDS). Adj EBITDA +21% to €78.7M, margin +280bps to 26%. Adj EPS €0.14 vs €0.11. Balda divestiture €12.2M one-time cost, margin-accretive. Fishers/Latina ramping, CapEx moderating, FCF -€32M. Biologics 42% of BDS. Thesis: gap between reported earnings & fully-ramped power. Long $14.58.
Read full article (6 min)